Methods: This was a single-arm, non-randomized pilot study of carboplatin, taxane, and immune checkpoint inhibitor, pembrolizumab, followed by 12 months of maintenance pembrolizumab in patients with incompletely resected epithelial ovarian cancer (EOC). Results: A total of 29 patients...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1923, 127 (2022). https://doi.org/10.1007/s40278-022-22990-2 Download citation Published10 September 2022 Issue DateSeptember 2022 DOIhttps://doi.org/10.1007/s40278-022-22990-2 Access this article Log in via an institution Buy article PDF...
Carboplatin/paclitaxel/pembrolizumab. Reactions Weekly 1955, 121 (2023). https://doi.org/10.1007/s40278-023-38368-3 Download citation Published06 May 2023 Issue DateMay 2023 DOIhttps://doi.org/10.1007/s40278-023-38368-3 Access this article Log in via an institution Subscribe and save Springer...
Texas School of Public Health, Houston,TX, USA Introduction: Real-world comparative effectiveness, safety, and supportive care use of nab- paclitaxel plus carboplatin vs gemcitabine plus platinum were analyzed in patients with advanced or metastatic squamous cell non-small cell lung cancer (NSCLC). ...
The study KEYNOTE-407 investigated pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel or chemotherapy alone in patients with stage IV squamous NSCLC who had not received previous systemic therapy for metastatic disease.4 The addition of pembrolizumab to the chemotherapy ...
Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma ... D Zheng,A Mojebi,CM Black,... - 《Journal of Clinical Oncology》 被引量: 0发表: 2024年 Multicenter Phase 2 Trial of C is/Carbo...
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol, 20 (2019), pp. 924-937 View...
Selected KEYTRUDA® (pembrolizumab) Indications in the U.S. Endometrial Carcinoma KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary...
Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient. Anti-Cancer Drugs : no pagination, 18 Jan 2021. Available from: URL: http://doi.org/10.1097/CAD.0000000000001040 Download references Rights and permissions Reprints and permissions About ...
Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 8 (Suppl. 3): A118 abstr. 201, 2020. Available from: URL: http://doi.org/10.1136/jitc-2020-SITC2020.0201 [abstract]...